III - FundFactsheet

Investment Objective: The Company’s objective is to develop a portfolio of unquoted and quoted MedTech companies and to generate capital growth over the long term.

  Dealing Charge  Star Rating Risk Level   12 Month Performance
£10 - Medi-HighMedi-HighMedi-HighMedi-HighMedi-High 50.65 42.50
Quick Stats Purchase info
Currency: GBX Change on day 0.00% Sector IT VCT Specialist: Health & Biotech Min: -
Bid price: 43.00 YTD return 0.00% Market Value(£m) 3.65 ISA: No
Mid price: 45.00 Yield 0.00% Asset type VCT Discount(-)
/Premium(+)
-27.73
Offer price 47.00 Type ORDN Launch date 19/04/2002 Gearing % -
Performance - View all
Key Chart Instrument 1 mth 6 mths 1 yr 3 yrs
Seneca Growth Capital VCT PLC Ord 1P 0.00% -10.36% -2.17% -29.13%
IT VCT Specialist: Health & Biotech 0.00% -10.36% -1.09% -29.11%
Seneca Growth Capital VCT PLC Ord 1P NAV - -2.41 -3.32 -27.35



Sector/Region weightings are currently unavailable

Investment Objective

The Company’s objective is to develop a portfolio of unquoted and quoted MedTech companies and to generate capital growth over the long term.

Quick Stats
TIDM code HYG Legal structure VCT Currency GBX
ISIN code GB0031256109 Market Value £3.65 M at 18/09/2018 Price date 18/09/2018
Risk Level Medi-HighMedi-HighMedi-HighMedi-HighMedi-High Star rating - Pricing freq Daily
Sector IT VCT Specialist: Health & Biotech Valor code - WKN Code -
Bid price 43.00 Mid price 45.00 Offer Price 47.00
Benchmark No Specified Index Yield 0.00% Launch date 19/04/2002
Domicile United Kingdom Asset type ORDN ISA No
NAV 62.27 Discount (-)
/Premium(+)
-27.73 Gearing % -
Purchase & Other Information
Min.investment -
Min.top-up -
Standard (Fund Manager) Initial Charge -
Interactive Investor Initial Charge -
Ongoing Charges 2.20% at 31/12/2017
Compliant -
Dividend dates -
For sale in United Kingdom,
Performance Chart in (GBX)

Shareholder Total Return.

Past performance is not a guide to future performance. Fund performance data doesn’t take into account fees and expenses which are specific to individual plans. Details are available on request.

Cumulative Performance in GBX
  3 mth 6 mth 1 yr 3 yr 5 yr
Investment -3.02% -10.36% -2.17% -29.13% -36.62%
Sector -3.02% -10.36% -1.09% -29.11% -39.17%
Relative to sector 0.00% 0.00% -1.08% -0.02% 2.55%
Rank within sector 1/1 1/1 1/1 1/1 1/1
Quartile 1st 1st 1st 1st 1st
Discrete Annual Performance to Last Quarter End in GBX
  0-12m 12m-24m 24m-36m 36m-48m 48m-60m
Investment 2.27% -9.28% -27.07% 5.56% -13.03%
Sector 1.16% -8.25% -27.07% 5.56% -16.56%
Relative to sector 1.11% -1.03% 0.00% 0.00% 3.53%
Rank within sector 1/1 1/1 1/1 1/1 1/1
Quartile 1st 1st 1st 1st 1st
Performance by Calendar Year in GBX
  YTD 2017 2016 2015 2014
Investment 0.00% -5.26% -9.52% -20.45% -8.97%
Sector 0.00% -5.23% -9.52% -20.45% -8.97%
Relative to sector 0.00% -0.03% 0.00% 0.00% 0.00%
Rank within sector 1/1 1/1 1/1 1/1 1/1
Quartile 1st 1st 1st 1st 1st
Investment Price Movement
12 month high 50.65 (British Pence) 12 month low 42.50 (British Pence)
Risk Statistics
Volatility Alpha Beta Sharpe Tracking Error Information Ratio R2
Investment 15.18 0.46 1.03 -0.02 2.63 0.00 0.97
Asset Weightings as at June 30, 2018
Rank Change Name % Weighting
1 NoChange International Equities 100.00%
  •  Faller
  •  Riser
  •  No change
  • new  New entry
Region Weightings are currently unavailable
Sector Weightings are currently unavailable
Top Holdings as at June 30, 2018
Rank Change Name % Weighting
1 NoChange OR PRODUCTIVITY LIMITED 11.10%
2 NoChange HALLMARQ VETERINARY IMAGING LIMITED 10.20%
3 NoChange INSENSE LIMITED 4.60%
4 Riser IMMUNOBIOLOGY LIMITED 2.00%
5 Riser ARECOR LIMITED 1.90%
6 Riser MICROARRAY LIMITED 1.80%
7 Riser EXOSECT LIMITED 1.30%
8 NewEntry GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED 1.20%
9 NewEntry FUEL 3D TECHNOLOGIES LIMITED 1.00%
Total 35.10%
  •  Faller
  •  Riser
  •  No change
  • new  New entry